Tom Van Maerken
Corresponding Author: Tom Van Maerken
Ghent University Hospital
De Pintelaan 185
B-9000 Ghent
Belgium
Name/email consistency: high
- Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3. Van Maerken, T., Rihani, A., Dreidax, D., De Clercq, S., Yigit, N., Marine, J.C., Westermann, F., De Paepe, A., Vandesompele, J., Speleman, F. Mol. Cancer Ther. (2011)
- Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. Van Maerken, T., Ferdinande, L., Taildeman, J., Lambertz, I., Yigit, N., Vercruysse, L., Rihani, A., Michaelis, M., Cinatl, J., Cuvelier, C.A., Marine, J.C., De Paepe, A., Bracke, M., Speleman, F., Vandesompele, J. J. Natl. Cancer Inst. (2009)
- Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-p53 axis. Van Maerken, T., Vandesompele, J., Rihani, A., De Paepe, A., Speleman, F. Cell Death Differ. (2009)
- Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Van Maerken, T., Speleman, F., Vermeulen, J., Lambertz, I., De Clercq, S., De Smet, E., Yigit, N., Coppens, V., Philippé, J., De Paepe, A., Marine, J.C., Vandesompele, J. Cancer Res. (2006)